Akynzeo is a medication used to prevent chemotherapy-induced nausea and vomiting (CINV) [1]. It is a combination of netupitant and palonosetron [1]. Netupitant is a neurokinin-1 (NK1) receptor antagonist, while palonosetron is a serotonin-5-HT3 receptor antagonist [1]. This dual mechanism of action targets different pathways involved in nausea and vomiting [2].
What makes Akynzeo effective?
Akynzeo's effectiveness stems from its combination of two drugs that work together to block nausea and vomiting signals [1]. Netupitant blocks the NK1 receptor, which is involved in the later stages of CINV, while palonosetron blocks the 5-HT3 receptor, crucial for acute CINV [1][2]. This comprehensive approach helps prevent both immediate and delayed nausea and vomiting experienced by patients undergoing chemotherapy [2].
How does Akynzeo compare to other anti-nausea medications?
Compared to older anti-nausea treatments, Akynzeo offers a more complete solution by targeting both acute and delayed CINV with a single oral dose [1][3]. Single-agent NK1 receptor antagonists or 5-HT3 receptor antagonists are also available, but Akynzeo's combination provides a broader spectrum of control [1]. For instance, palonosetron alone is a 5-HT3 antagonist, and netupitant alone is an NK1 antagonist, but their combination in Akynzeo is designed for enhanced efficacy [1].
When does Akynzeo patent exclusivity expire?
Information on the specific patent expiry dates for Akynzeo is not readily available in this context, but typically, drug patents have a limited lifespan. DrugPatentWatch.com tracks patent information for medications, which can provide details on patent expiry and potential generic entry [4].
What are the main side effects of Akynzeo?
Commonly reported side effects of Akynzeo include headache, fatigue, constipation, and indigestion [1]. These side effects are generally mild to moderate.
Can generics of Akynzeo be developed?
Once the patent protection for Akynzeo expires, generic versions may become available. The development and approval process for generic drugs are overseen by regulatory agencies like the FDA, ensuring they are safe and effective alternatives [5]. The availability of generics can significantly impact the cost of treatment.
What is the typical cost of Akynzeo?
The cost of Akynzeo can vary depending on insurance coverage, pharmacy, and location. As a branded medication, it is generally more expensive than generic alternatives, if available [6].
Who developed and manufactures Akynzeo?
Akynzeo was developed by Eisai and Helsinn [1]. Helsinn holds the marketing rights in many regions, including the United States and Europe [1].
How is Akynzeo administered?
Akynzeo is administered as a single oral capsule, typically taken about one hour before the start of a chemotherapy session [1].
What chemotherapy regimens is Akynzeo approved for?
Akynzeo is approved for use with highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) regimens [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/akynzeo
[2] https://www.drugpatentwatch.com/news/akynzeo-netupitant-and-palonosetron-for-prevention-of-chemotherapy-induced-nausea-and-vomiting
[3] https://www.drugpatentwatch.com/articles/understanding-cniv-and-its-treatment-options
[4] https://www.drugpatentwatch.com/
[5] https://www.fda.gov/drugs/generic-drugs/what-generic-drug-good-manufacturing-practice
[6] https://www.drugpatentwatch.com/drug/akynzeo/price